Protalix BioTherapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-32.1M | $-32.9M | $849.0K | $988.0K |
| FY2017 | $-10.0M | $-11.0M | $971.0K | $337.0K |
| FY2018 | $-7.7M | $-8.4M | $686.0K | $514.0K |
| FY2019 | $-19.4M | $-20.0M | $627.0K | $835.0K |
| FY2020 | $-26.1M | $-26.8M | $655.0K | $3.1M |
| FY2021 | $-10.3M | $-11.7M | $1.5M | $2.4M |
| FY2022 | $-25.0M | $-25.6M | $628.0K | $2.1M |
| FY2023 | $-1.3M | $-2.5M | $1.1M | $3.4M |
| FY2024 | $8.7M | $7.4M | $1.3M | $3.3M |
| FY2025 | $-12.0M | $-13.6M | $1.6M | $2.3M |